Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 10/20 | 0.41 |
| ▸ | CCKBR | P32239 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268176 | 0.91 | CHRM1 (0.40) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL2268380 | 0.90 | CCKBR (0.41) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL3231240 | 0.87 | CHRM1 (0.38) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL2264526 | 0.86 | CHRM1 (0.44) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL2269267 | 0.85 | MEN1 (0.39) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL2267540 | 0.83 | CCKBR (0.41) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL2264477 | 0.82 | CCKBR (0.57) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL2268675 | 0.81 | MEN1 (0.43) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL2267642 | 0.81 | LMNA (0.44) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL2962352 | 0.80 | OPRK1 (0.40) | CHRM1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289498-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242109-B2 | Compositions and methods relating to novel compounds and targets thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110195959-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-11 | — | — | US | disclosed |
| US-7851465-B2 | Compositions and methods relating to novel compounds and targets thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195959-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | BAX, BAD, BAK1 | CHRM1 2574/4885CCKBR 416/4885MEN1 4283/4885 |
| US-20120289498-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | BAX, BAD, BAK1 | CHRM1 2574/4885CCKBR 416/4885MEN1 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.